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Signal transduction and regulation
Gene-modified mice
Spred2a b s t r a c t
Introduction: Mitogen-activated protein kinases (MAPKs) are involved in T cell-mediated liver damage.
However, the inhibitory mechanism(s) that controls T cell-mediated liver damage remains unknown.
Objectives: We investigated whether Spred2 (Sprouty-related, EVH1 domain-containing protein 2) that
negatively regulates ERK-MAPK pathway has a biological impact on T cell-mediated liver damage by
using a murine model.
Methods: We induced hepatotoxicity in genetically engineered mice by intravenously injecting
Concanavalin A (Con A) and analyzed the mechanisms using serum chemistry, histology, ELISA, qRT-
PCR, Western blotting and flow cytometry.
Results: Spred2-deficient mice (Spred2-/-) developed more sever liver damage than wild-type (WT) mice
with increased interferon-c (IFNc) production. Hepatic ERK phosphorylation was enhanced in Spred2-/-
mice, and pretreatment of Spred2-/- mice with the MAPK/ERK inhibitor U0126 markedly inhibited the
liver damage and reduced IFNc production. Neutralization of IFNc abolished the damage with decreased
hepatic Stat1 activation in Spred2-/- mice. IFNc was mainly produced from CD4+ and CD8+ T cells, and
their depletion decreased liver damage and IFNc production. Transplantation of CD4+ and/or CD8+ T cellsrferon-
C. Sun, M. Fujisawa, T. Ohara et al. Journal of Advanced Research xxx (xxxx) xxxfrom Spred2-/- mice into RAG1-/- mice deficient in both T and B cells caused more severe liver damage
than those from WT mice. Hepatic expression of T cell attractants, CXCL9 and CXCL10, was augmented
in Spred2-/- mice as compared to WT mice. Conversely, liver damage, IFNc production and the recruit-
ment of CD4+ and CD8+ T cells in livers after Con A challenge were lower in Spred2 transgenic mice,
and Spred2-overexpressing CD4+ and CD8+ T cells produced lower levels of IFNc thanWT cells upon stim-
ulation with Con A in vitro.
Conclusion: We demonstrated, for the first time, that Spred2 functions as an endogenous regulator of T
cell IFNc production and Spred2-mediated inhibition of ERK-MAPK pathway may be an effective remedy
for T cell-dependent liver damage.
 2021 The Authors. Published by Elsevier B.V. on behalf of Cairo University. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Table 1
Antibodies for Western blotting and flow cytometry.
Western blotting
Bcl2 Cell Signaling Technology (3498)
GAPDH Cell Signaling Technology (5174)
p44/42 MAPK (ERK1/2) Cell Signaling Technology (4695)
phospho-p44/42 MAPK (pERK1/2)
(Thr 202/Tyr 204)
Cell Signaling Technology (4370)
STAT1 Cell Signaling Technology (9172)
phospho-STAT1 (Tyr 701) Cell Signaling Technology (9167)
STAT3 Cell Signaling Technology (12640)
phospho-STAT3 (Tyr 705) Cell Signaling Technology (9145)
HRP-goat anti-rabbit IgG Cell Signaling Technology (7074)
HRP-anti-mouse IgG Cell Signaling Technology (7076)
Flowcytometry
CD16/32 BioLegend (101302)
FITC-CD3 (17A2) BioLegend (100204)
PE-CD4 (GK1.5) BD Pharmingen (553730)
FITC-CD8 (53–6.7) BioLegend (100706)
PE-CD8 (53–6.7) BioLegend (100708)
PE-NK1.1 (PK136) BioLegend (108708)
FITC-IFNc (XMG1.2) BioLegend (505806)Introduction
The liver is an immunologic organ prone to viral infection and
autoimmune disorders. A major cellular component that causes
the hepatic damage is immune cell populations, mainly T cells
[1,2]. CD4+ and CD8+ T cells are involved in the development of
viral hepatitis and autoimmune hepatitis (AIH) [3,4]. Infiltrating
T cells provoke a progressive hepatocyte damage with interface
hepatitis, resulting in the progression of liver fibrosis. Understand-
ing a mechanism(s) governing T cell-mediated hepatitis continues
to be a significant challenge [1].
When activated, CD4+ and CD8+ T cells generate interferon-c
(IFNc), and IFNc production is significantly elevated in patients
with viral hepatitis and AIH [5–7]. To elucidate the pathogenesis
of T cell-mediated hepatitis, studies using animal models are
important. The most frequently used mouse model for investigat-
ing T cell-dependent liver damage is a systemic injection of Con-
canavalin A (Con A) [8]. Con A is an antigen-independent
mitogen that activate T cells, resulting in hepatocyte damage [9].
IFNc directly and indirectly causes hepatocellular apoptosis and
necrosis during Con A-hepatotoxicity [10,11]. Con A-
hepatotoxicity was ameliorated in mice with IFNc deficiency [11].
The mitogen-activated protein kinases (MAPKs) are constituted
by 3 serine/threonine kinases [12]. Among MAPKs, extracellular
regulated kinase (ERK)-1/2 is important in IFNc responses [13].
ERK activation was found in Con A-induced liver damage and the
MAPK/ERK inhibitor U0126 inhibited Con A-stimulated prolifera-
tion of CD4+ T cells [14]. Thus, ERK-MAPK overactivation may con-
tribute to exacerbated Con A-hepatotoxicity by enhancing T cell
responses, such as IFNc production.
Signaling pathways are counterbalanced by endogenous inhibi-
tory mechanism(s). Spred2 (Sprouty-related, EVH1 domain-
containing protein 2) binds to Ras and inhibits the downstream
of the Ras/Raf/ERK-MAPK pathway [15]. We have hitherto investi-
gated the function of Spred2 in several models of acute inflamma-
tion and demonstrated that Spred2 in macrophages is essential in
downregulating inflammatory responses [16–20]. Spred2-deficient
(Spred2-/-) mice were vulnerable to hepatotoxicity induced by
acetaminophen (APAP) and lipopolysaccharide/D-Galactosamine
(LPS/D-Gal) due to up-regulated ERK activation [18,20]. Although
the in vivo manifestations, represented by increased alanine
transaminase (ALT) and tissue damage, are similar among the
models, the etiology and molecular mechanism(s) are different.
APAP-induced liver injury model represents drug-induced liver
injury, in which APAP overdose mainly causes direct hepatocyte
injury, resulting in secondary liver damage by subsequent leuko-
cyte responses [21]. LPS/D-Gal-induced liver injury model repre-
sents liver injury during sepsis, which is suitable for investigating
TNFa-mediated apoptosis [22]. Con A-hepatotoxicity is a model of
T cell-mediated liver damage [8], which is regarded as a relevant
model of viral hepatitis and AIH. To gain a deeper understanding
of the function(s) of Spred2 in liver pathology, it is vitally impor-2
tant to explore the molecular mechanisms in all these liver injury
models.
In the present study, we aimed to investigate whether Spred2
plays any role in T cell-mediated liver damage by injecting Con A
into Spred2-/- and Spred2 transgenic (Spred2Tg) mice. We demon-
strated that endogenous Spred2 is protective in Con A-
hepatotoxicity by inhibiting CD4+ and CD8+ T cell IFNc production
via downregulating the ERK-MAPK pathway.Materials and methods
Reagents
Con A was obtained from Sigma-Aldrich (St. Louis, MO, USA).
Recombinant mouse IFNc and U0126 were purchased from BioLe-
gend (San Diego, CA, USA) and Promega (Madison, WI, USA),
respectively. Antibodies used for Western blotting and flow cytom-
etry were listed in Table 1.
Mice
The generation of Spred2-/- mice in C57BL/6J background were
previously described [23]. C57BL/6J mice were employed as wild-
type mice (WT). RAG1 (recombination-activating protein 1) defi-
cient mice (RAG1-/-) were obtained from Charles River Laboratories
(Yokohama, Japan). To generate Spred2-overexpresion mice
(Spred2Tg), pCAGGS-Spred2 expression vector was constructed by
inserting coding region of Spred2 cDNA into a pCAGGS vector,
which contains CAG promoter (chimeric promoter of CMV IE
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intron, rabbit beta-globin second intron, third exon and 30 flanking
region [24](Fig. S1). Coding region sequence of Spred2 cDNA was
chemically synthesized with the Kozak consensus sequence at 50
end and EcoRI site at both ends. Synthesized fragment was digested
with EcoRI and inserted at EcoRI site on pCAGGS vector, between
beta-globin third intron and 30 flanking region (Fig. S1). The puri-
fied transgene DNA was used for micro-injection into the pronu-
cleus of C57BL/6 mouse fertilized eggs, and eggs were transferred
to the oviducts of pseudo-pregnant mice to generate transgenic
mice. For genotyping of transgenic mice, following primer set
was used; pCAGGS-F1: 50-GTCGACATTGATTATTGACTAGTTATTAA
TATGAATC-30 and R2275: 50-GTCGAGGGATCTCCATAAGAGAA
GAGGCAGA-30. Eighty-two mice were obtained from injected
embryos, and 7 mice had the transgene. The founder mice were
then crossed with C57BL/6J wild-type females, and hemizygous
F1 mice were obtained. Generation of transgenic mice was per-
formed in Transgenic Inc. (Kobe Japan) with institutional Animal
Research Committee approval. Hemizygous mice were then
crossed with C57BL/6J mice, and mice with transgene were used
as Spred2Tg mice. Non-transgenic littermates were used as WT
mice.
All mice used in this study were bred and maintained under a
continuous 12 h light/12 h dark cycle in a specific pathogen-free
condition at the Department of Animal Resources, Okayama
University (Okayama, Japan). Female mice (6–8 weeks of age) were
employed in this study.
Ethics statement
All experiments involving animals were conducted according to
the ethical policies and procedures approved by The Animal Care
and Use Committee of Okayama University (Approved No. OKU-
2016557, OKU-2019034).
Liver injury model
Con A (10 mg/kg body weight) was injected once into mice
through tail vein to induce acute liver damage. At indicated times
after Con A challenge, mice were anesthetized and euthanized.
After perfusion with sterile saline, livers were resected and stored
at 80 C for detection of mRNA and protein expression. Part of the
liver was fixed with 10% formalin solution and 4-mm paraffin sec-
tions were stained with hematoxylin and eosin (HE). Three inde-
pendent pathologists evaluated the sections. To measure %injured
area, HE sections were captured under microscope and analyzed
using a microscopy imaging software (cellSens Standard; Olympus,
Tokyo, Japan). For monitoring mice survival, mice were received a
sublethal dose (15 mg/kg) of Con A through tail vein. In different
sets of experiments, mice were intraperitoneal administered with
10 lmol/kg U0126 or vehicle (DMSO) 3 h prior to 10 mg/kg Con
A injection. To neutralize endogenous IFNc, rabbit anti-mouse IFNc
IgG or control rabbit IgG (1 mg/mouse) was intraperitoneally
injected 12 h prior to 10 mg/kg Con A. To deplete CD4+ or CD8+ T
cells, mice received intraperitoneal administration of anti-CD4
(L3T4, 100 lg/mouse) or anti-CD8 mAb (Lyt-2.2, 100 lg/mouse)
[25], 12 h prior to 10 mg/kg Con A. Isotype matched control rat
IgG was used as control.
Caspase assay
Livers were homogenized, centrifuged, and the cleared super-
natants were harvested. One hundred lg of extracts were used
for measuring caspase-3, caspase-8, and caspase-9 activities
(Colorimetric assay kits; MBL, Nagoya, Japan).3
Cell isolation and culture
Splenocytes were harvested from spleens after dispersing into
cell-suspensions. CD4+ and CD8+ T cells were isolated from
splenocyte-suspensions (purity and %alive cells > 95%) using
CD4+ and CD8a+ T cell isolation kit (Miltenyi Biotec, Bergisch Glad-
bach, Germany), respectively. Cells (5  106 cells/mL) were cul-
tured with 10 lg/mL Con A.Leukocyte isolation from livers
After perfusion with saline, livers were removed, chopped and
digested with 5 mL digestion buffer (HBSS containing 20 mM
HEPES, pH 7.4, plus 0.02% w/v collagenase, 0.0005% w/v DNase I)
for 30 min using gentleMACSTM Dissociator (Miltenyi Biotec). After
filtering through 100-lm nylon mesh, cells were washed, cen-
trifuged, and the resultant cell pellets were suspended in 35% Per-
coll. After centrifugation, cell pellets were washed, and cell
numbers were counted under microscope.Hepatocyte isolation and culture
Hepatocyte isolation was carried out, as described previously
[26]. Isolated hepatocytes (>95% alive) were suspended in hepato-
cyte maintenance medium (Thermo fisher), distributed onto colla-
gen I-coated plates (1.3  105 cells/well, CORNING, Kennebunk,
ME, USA) and incubated overnight. Hepatocytes were cultured
with 40 ng/mL IFNc for 6 h (for chemokine expression by cells)
or 48 h (for lactate dehydrogenase (LDH) release in the
supernatants).Cell transplantation
Purified CD4+ T cells (2.5  106 cells/mouse) or CD8+ T cells
(5  106 cells/mouse) were injected into RAG1-/- mice deficient
in both T and B cells through tail vein, 1 week before 10 mg/kg
Con A challenge.Real-time quantitative PCR (RT-qPCR)
Total RNA was isolated from cells and livers using High Pure
RNA Isolation Kit (Roche Applied Science, Mannheim, Germany)
and Trizol Reagent (Thermo Fisher), respectively. First-strand
cDNAs were synthesized from 2 mg total RNA using High capacity
cDNA reverse transcription kit (Thermo Fisher). RT-qPCR was run
on a StepOnePlus system (Thermo Fisher). Gene expression level
of interest was normalized using that of GAPDH expression. Taq-
man gene expression assays (Thermo Fisher) used in this study
were shown in Table 2.Western blotting
Cells and livers were lysed in a lysis buffer (Cell Signaling), cen-
trifuged, and cleared supernatants were harvested. Proteins in each
lysate (10 mg) were fractionated by SDS-polyacrylamide gel elec-
trophoresis (Thermo Fisher) and transferred onto nitrocellulose
membranes. After blocking, the membranes were incubated over-
night with a primary antibody. The membranes were washed
and then incubated with horseradish peroxidase-conjugated sec-
ondary antibody. Target proteins were visualized by ImmunoStar
LD (Wako, Osaka, Japan) and quantitated using C-DiGit Blot scan-
ner (LI-COR Biotechnology, Lincoln, Nebraska, USA). The images
were semi-quantitated with Image Studio software.
Table 2
Taqman gene expression assays used for RT-qPCR.
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After Fc blocking with anti-CD16/CD32 antibody, cells were
incubated with antibodies of interest or isotype control rat IgG
and cell populations were examined using a Cell Lab Quanta SC
MPL (Beckman Coulter, Inc., Brea, CA). Lymphocytes were gated
using Electronic Volume (EV) versus Side Scatter (SS) in a dual
parameter gate, and then analyzed the percentage of each cell pop-
ulation among gated lymphocytes. For IFNc intracellular staining,
IFNc antibody was diluted in fixation/permeabilization buffers
(eBioscience, San Diego, CA, USA). The number of each leukocyte
population per liver was determined from the respective percent-
age and total number of hepatic leukocytes.
Elisa
IFNc, TNFa and IL-12 levels were determined using a standard
sandwich ELISA (BioLegend). These ELISAs did not recognize other
murine cytokines available.
Statistics
Data were analyzed using GraphPad Prism 7 (GraphPad Soft-
ware, San Diego, CA, USA). After assessments of the normality of
data, statistical significance was analyzed by parametric two-
tailed unpaired t test and non-parametric Mann Whitney u test
for normal distribution and non-normal distribution, respectively.
Data were expressed as the mean ± SEM, (normal distribution) or
median ± range (non-normal distribution). All test results includ-
ing mean, median, range, exact-p value and test method were sum-
marized in supplementary table 1. Survival rate was compared
using the log-rank test. A p value < 0.05 was considered statistically
significant.
Results
Spred2-/- mice exhibit exacerbated liver damage via enhanced ERK
activation
To examine a potential involvement of Spred2 in Con
A-hepatotoxicity, we employed Spred2-/- mice. No difference was
found in serum ALT level between naive WT and Spred2-/- mice
(65.0 ± 5.0 vs 53.3 ± 14.5 IU/L, respectively, 4 mice each). Upon
injection of 10 mg/kg Con A, increased ALT levels (Fig. 1A) and aug-
mented injured area represented by hepatocyte necrosis with infil-
trating leukocytes (Fig. 1B) were detected in Spred2-/- mice relative
to WT mice. Survival rate of Spred2-/- mice after injecting a sub-
lethal dose (15 mg/kg) of Con A was lower than that of WT mice
(Fig. 1C). Con A-hepatotoxicity is shown to be accompanied by
increased caspases activates, important for the induction of hepa-
tocyte apoptosis [27]. As shown in Fig. 1D, activities of caspase-3,
8, and 9 in Spred2-/--livers after 10 mg/kg Con A challenge were
significantly augmented, as compared to WT-livers. In contrast,4
hepatic levels of bcl-2, anti-apoptotic factor, were reduced in
Spred2-/--livers as compared to WT-livers (Fig. 1E). Thus, Spred2-
deficiency is deleterious in Con A-induced liver damage.
The key molecules involved in Con A-hepatotoxicity are MAPKs,
including ERK [14]. The enhanced hepatotoxicity in Spred2-/- mice
may result from the augmented ERK-MAPK pathway. As shown in
Fig. 1F, activation of ERK, indicated by phosphorylated ERK/total
ERK (pERK/tERK) ratio, was weak in livers from untreated WT
and Spred2-/- mice. ERK activation at 12 h post Con A challenge
was evident in WT-livers, which was further augmented in
Spred2-/--livers (Fig. 1F). U0126, a MAPK/ERK inhibitor, reduced
ERK activation in WT- and Spred2-/--livers (Fig. 1G), and protected
WT and Spred2-/- mice from liver damage, as estimated by
decreased ALT levels (Fig. 1H) and reduced injured area (Fig. 1I).
These data indicated that exacerbated liver damage in Spred2-/-
mice was dependent on enhanced ERK activation.
IFNc is ascribed to enhanced hepatotoxicity in Spred2-/- mice
Since T helper 1 cytokines that include IFNc, TNFa and IL-12 are
known involved in Con A-hepatotoxicity [28], levels of these
cytokines were examined. At 12 h post Con A challenge, hepatic
IFNcmRNA expression level and serum IFNc level in Spred2-/- mice
were higher than that in WT mice (Fig. 2A, B). No differences were
found in the expression of TNFa and IL-12 at mRNA and protein
level between WT and Spred2-/- mice (Fig. 2A, B). Increased IFNc
levels in livers (Fig. 2C) and circulation (Fig. 2D) were reduced by
U0126, both in WT and Spred2-/- mice, relative to control.
In response to Con A, Stat proteins, such as Stat1 and Stat3, are
activated and mediate liver damage [29]. Fig. 3A demonstrated
that phosphorylation of Stat1, but not Stat3, was increased in
Spred2-/--livers as compared to WT-livers after Con A challenge.
STAT1 in the liver is predominately activated by IFNc, and we
found neutralization of IFNc in Spred2-/- mice decreased Stat1 acti-
vation, but not Stat3 activation, in the liver (Fig. 3B). Interestingly,
U0126 treatment of Spred2-/- mice significantly decreased Stat1
activation in Spred2-/--livers relative to the controls (Fig. 3C). To
further elucidate the contribution of IFNc to the liver damage in
Spred2-/- mice, the degree of liver damage was evaluated after neu-
tralization of IFNc. Neutralization of IFNc dramatically reduced
Con A-hepatotoxicity in Spred2-/- mice, as serum levels of ALT were
inhibited by 93% (Fig. 3D) and injured area were reduced by 94% by
histological examination (Fig. 3E), as compared to controls. These
results indicate that exacerbated hepatotoxicity in Spred2-/- mice
is ascribed to the enhanced IFNc production. Further, the enhanced
IFNc production in Spred2-/- mice was due to the enhanced ERK-
MAPK signaling, potentially in T cells, resulting in subsequent Stat1
activation and exacerbated liver damage.
CD4+ and CD8+ T cells are ascribed to increased IFNc production and
liver damage in Spred2-/- mice
We examined the effect of Spred2-deficiency on the capacity of
T cells to produce IFNc. We first isolated splenocytes from Con A-
treated mice and cultured for 24 h without additional stimulation.
As shown in Fig. 4A, Spred2-/--splenocytes released higher level of
IFNc than WT controls. Next, splenocytes from naive mice were
stimulated with Con A in vitro. Again, Spred2-/--splenocytes pro-
duced higher levels of IFNc than WT controls (Fig. 4B). ERK activa-
tion is important for T cell function [30]. As shown in Fig. 4C, ERK
activation in naive WT- and Spred2-/--splenocytes was weak,
which was significantly augmented in Spred2-/--splenocytes after
Con A stimulation as compared to WT controls. IFNc activates
Stat1 signaling pathway during Con A-hepatotoxicity [29]. Stat1
is known activated in CD4+ T cells after Con A injection in vivo
[31,32]. As shown in Fig. 4D, Stat1 activation in Spred2-/--
Fig. 1. Spred2-/- mice exhibit exacerbated Con A-induced liver damage via enhanced ERK activation. (A) Serum ALT levels in WT and Spred2-/- mice were measured post
10 mg/kg Con A challenge (4–12 mice, each). (B) Left; liver sections from WT and Spred2-/- mice at 12 h post 10 mg/kg Con A challenge (scale bar, 100 mm). Right; %injured
area was estimated using cellSens Standard software (6 mice, each). (C) Survival of WT (20 mice) and Spred2-/- mice (20 mice) after a sublethal dose (15 mg/kg) of Con A
challenge was monitored. (D) Caspase-3, 8, 9 activities in WT-livers (5–8 mice) and Spred2-/--livers (8 mice) were determined at 12 h post 10 mg/kg Con A challenge. (E,F)
Liver extracts at 12 h post 10 mg/kg Con A challenge were immunoblotted with indicated primary antibodies (E; 3 mice each, F; 4 mice each). Band densities were digitised
and semi-quantitated. (G,H) WT and Spred2-/- mice were intraperitoneally injected with 10 lmol/kg U0126 or DMSO 3 h before 10 mg/kg Con A challenge. (G) The level of
each protein in livers at 12 h post 10 mg/kg Con A challenge was evaluated by Western blotting using the indicated primary antibodies (3 mice each). Band densities were
semi-quantitated. (H) ALT levels in the sera at 12 h post 10 mg/kg Con A challenge were measured (DMSO; 6 mice, U0126; 4 mice). (I) Spred2-/- mice were intraperitoneally
injected with 10 lmol/kg U0126 or DMSO 3 h before 10 mg/kg Con A challenge. Left; representative photographs of liver sections at 12 h post Con A challenge (scale bar,
100 mm). Right; %injured area was estimated using cellSens Standard software (DMSO; 6 mice, U0126; 4 mice). *p < 0.05., **p < 0.01., ***p < 0.001.
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Fig. 2. Cytokine response in Spred2-/- mice. (A) IFNc, TNFa and IL-12 p40 mRNA expressions in WT- and Spred2-/--livers after 10 mg/kg Con A challenge were analyzed by
RT-qPCR (4–10 mice, each time point). (B) Serum IFNc, TNFa and IL-12 levels inWT and Spred2-/- mice at 12 h post 10 mg/kg Con A challenge were measured by ELISA (10–11
mice, each). (C,D) WT and Spred2-/- mice were intraperitoneally administered with 10 lmol/kg U0126 or DMSO 3 h prior to 10 mg/kg Con A challenge. IFNcmRNA expression
in livers (C) and IFNc level in sera (D) at 12 h post Con A challenge were evaluated by RT-qPCR and ELISA, respectively (4–6 mice, each). *p < 0.05., ** p < 0.01., ***p < 0.001.,
**** p < 0.0001.
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U0126 dramatically abolished the Stat1 activation in both WT-
and Spred2-/--splenocytes (Fig. 4E). Thus, splenocytes produce IFNc
in response to Con A, which was enhanced in Spred2-/--cells
through augmented ERK activation, resulting in subsequent Stat1
activation.
We next investigated T cell infiltration in livers after Con A chal-
lenge. The total number of leukocytes at 12 h post Con A challenge
was increased in Spred2-/--livers compared to WT-livers (Fig. 5A).
Flow cytometry showed that the percentage and the number of
infiltrating CD4+ and CD8+ T cells were higher in Spred2-/--livers
than in WT-livers (Fig. 5B). No differences were found in the per-
centage and the number of NKT and NK cells between the groups.
Numbers of CD4+ T, CD8+ T, NKT, and NK cells were similar
between naive WT and Spred2-/- mice (0.73 ± 0.08 vs 0.94 ± 0.08
 106 cells, 0.19 ± 0.05 vs 0.18 ± 0.03  106 cells, 0.33 ± 0.09 vs
0.57 ± 0.05  106 cells, 0.72 ± 0.11 vs 0.75 ± 0.06  106 cells respec-
tively, 4 mice each). To examine the cellular source of enhanced6
IFNc production in livers, we performed intracellular IFNc staining.
Fig. 5C demonstrated that numbers of IFNc-producing CD4+ and
CD8+ T cells in Spred2-/--livers were higher than WT-livers, while
those of NKT and NK cells were comparable between the groups.
To further confirm the results, splenic CD4+ and CD8+ T cells from
naive WT and Spred2-/- mice were stimulated with Con A in vitro.
Both WT-CD4+/CD8+ T cells constitutively expressed Spred2, and
expression levels were increased at 6 h after Con A stimulation
(Fig. S2), suggesting a role of endogenous Spred2 in T cell function.
Upon stimulation with Con A, Spred2-/--CD4+ and CD8+ T cells gen-
erated higher levels of IFNc than WT controls (Fig. 5D) .To verify
the enhanced IFNc producing capability of CD4+ and CD8+ T cells
in Spred2-deficiency, Spred2-/--CD4+ and CD8+ T cells were cul-
tured with anti-CD3/CD28, which provides antigen-independent
signaling of the TCR complex [33]. Under the conditions, enhanced
IFNc production in Spred2-/--CD4+ and -CD8+ T cells were also
observed (Fig. 5E). When ERK pathway was blocked by U0126,
higher production of IFNc in Spred2-/--CD4+ and -CD8+ T cells were
Fig. 3. Neutralization of IFNc reduces Con A-induced Stat1 activation and liver damage. (A) Con A (10 mg/kg) was intravenously injected into WT and Spred2-/- mice. The level
of each protein in liver extracts at 12 h post Con A challenge was evaluated by Western blotting using the indicated primary antibodies (3 mice, each). Band densities were
semi-quantitated at 12 h post Con A challenge. (B) Spred2-/- mice were intraperitoneally administered with anti-mouse IFNc IgG (1 mg/mouse) or control rabbit IgG 12 h prior
to 10 mg/kg Con A challenge. The level of each protein in liver extracts at 12 h post Con A challenge was evaluated by Western blotting using the indicated primary antibodies
(3 mice, each). Band densities were semi-quantitated. (C) Spred2-/- mice were intraperitoneal injected with 10 lmol/kg U0126 or DMSO 3 h prior to 10 mg/kg Con A challenge.
The level of each protein in liver extracts at 12 h post Con A challenge was evaluated by Western blotting using the indicated primary antibodies (3 mice per group). Band
densities were semi-quantitated. (D, E) Anti-mouse IFNc IgG (1 mg/mouse) or control rabbit IgG was intraperitoneally injected into Spred2-/- mice 12 h prior to 10 mg/kg Con
A challenge. (D) Serum ALT levels at 12 h post Con A challenge were measured (control; 4 mice, anti-IFNc-treated; 6 mice). (E) Left; representative photographs of H&E-
stained liver sections (scale bar, 100 mm) are shown. Right; %injured area was estimated using the cellSens Standard software (control; 4 mice, anti-IFNc-treated; 6 mice).
*p < 0.05., **p < 0.01.
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Fig. 4. Enhanced IFNc production in Spred2-deficiency with augmented activation of ERK and Stat1. (A) Splenocytes harvested from WT and Spred2-/- mice at 12 h post
10 mg/kg Con A challenge were cultured for 24 h without additional stimulation (n = 12). IFNc levels in the culture supernatants were measured. (B) Splenocytes harvested
from naive WT and Spred2-/- mice were cultured with 10 lg/mL Con A for 24 h (n = 9). IFNc levels in the culture supernatants were quantitated. (C) Splenocytes isolated from
naive WT and Spred2-/- mice were cultured with 10 lg/mL Con A for 15 and 30 min. The level of each protein in cells was evaluated by Western blotting using the indicated
primary antibodies (3 each). Band densities were semi-quantitated. (D, E) Splenocytes isolated from naive WT and Spred2-/- mice were cultured with 10 lg/mL Con A (D) and
10 lM U0126 or DMSO (E) for 1 and 2 h. The level of each protein in cells was evaluated by Western blotting using the indicated primary antibodies (3 each). Band densities
were digitised and semi-quantitated. *p < 0.05., **p < 0.01., ***p < 0.001., **** p < 0.0001.
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stimulation (Fig. 5G). Thus, Spred2-deficiency results in a higher T
cell IFNc producing capacity.
CD4+ and CD8+ T cells are attracted by IFNc-inducible chemo-
kine CXCL9 and CXCL10 [34]. In Spred2-/- mice, hepatic mRNA
levels of CXCL9 and CXCL10 at 12 h post Con A challenge were
higher than WT controls, while CXCL9 level was not statistically
significant between the groups (Fig. 6A). Hepatic mRNA expression
of CXCL9 and CXCL10 in Spred2-/- mice was reduced by 79% and
97%, respectively, after IFNc neutralization (Fig. 6B), indicating that
IFNc induced CXCL9 and CXCL10 mRNA expression in Spred2-/-
mice. U0126 treatment reduced not only IFNc (Fig. 2C,D) but
CXCL9 and CXCL10 expressions in both WT- and Spred2-/--livers
(Fig. 6C). IFNc was previously shown to stimulate hepatocytes to
produce CXCL9 and CXCL10 [35,36]. Upon IFNc stimulation for
6 h in vitro, primary hepatocytes (purity > 95%) harvested from
naive Spred2-/- mice expressed increased CXCL9 and CXCL10 levels
compared withWT controls (Fig. 6D). Thus, increased IFNc produc-
tion in Spred2-/- mice induced enhanced CXCL9 and CXCL10
expression, possibly leading to augmented infiltration of CD4+
and CD8+ T cells in livers.CD4+ and CD8+ T cells are responsible for enhanced hepatotoxicity in
Spred2-/- mice
To further define the biological function of CD4+ and CD8+ T
cells in enhanced Con A-hepatotoxicity in Spred2-/- mice, Spred2-/-8
mice were intraperitoneally injected with anti-CD4+, anti-CD8+
antibody, or control rat IgG 12 h prior to Con A challenge
(Fig. S3). In Spred2-/- mice, depletion of CD4+ and CD8+ T cells
reduced ALT level by 95.7% and 46.1%, respectively. No additional
reduction was found after injection of both anti-CD4+ and anti-
CD8+ antibody (Fig. 7A). Serum levels of IFNc (Fig. 7B) and IFNc
expressions in livers (Fig. 7C) were significantly decreased after
depletion of CD4+ and CD8+ T cells. Next, CD4+ and CD8+ T cells iso-
lated from naive WT and Spred2-/- mice were transplanted into
RAG1-/- mice deficient in both T and B cells (Fig. S4). Consistent
with previous studies [37], no increase in ALT level was found in
RAG1-/- mice at 12 h post Con A challenge (non-treated; 29.5 ± 1.
3 IU/L., 12 h post ConA challenge; 25.3 ± 3.4 IU/L, 4 mice each).
RAG1-/- mice received Spred2-/--CD4+ and CD8+ T cells showed
enhanced liver damage after Con A challenge, as estimated by
increased levels of serum ALT (Fig. 7D,G) and histological tissue
damage (Fig. 7E,H), relative to those transferred with WT-cells.
Serum IFNc levels were also increased in mice transferred with
Spred2-/--CD4+ and CD8+ T cells (Fig. 7F,I). Interestingly, Con A-
induced tissue damage upon Spred2-/--CD4+ T cell transfer was
more severe than Spred2-/--CD8+ T cell transfer, despite the num-
ber of transferred CD8+ T cells was twice as many as that of CD4+
T cells. Together with the neutralizing studies (Fig. 7A,B), Spred2-
deficiency in CD4+ T cells may be more critical in liver damage than
that in CD8+ T cells in Con A-hepatotoxicity.
CD8+ T cells may exhibit the cytolytic activity by releasing
perforin and granzyme B [38]. Although no differences were
found in perforin and granzyme B mRNA expressions between
Fig. 5. CD4+ and CD8+ T cells are responsible for increased IFNc through the ERK/MAPK pathway. (A) The numbers of infiltrating leukocytes at 12 h post 10 mg/kg Con A
challenge were counted (4 mice, each). (B) Hepatic leukocytes were stained with fluorescence-labelled antibodies and percentages of leukocyte populations were analyzed by
flow cytometry (4 mice, each). (C) IFNc-producing cell types in livers at 12 h post 10 mg/kg Con A challenge were examined by flow cytometer (5 mice, each). (D) CD4+ and
D8+ T cells isolated from WT- and Spred2-/--spleens were cultured with 10 lg/mL Con A for 6, 12 and 24 h, and IFNc levels in the culture supernatants were determined (5
mice, each). (E) CD4+ and CD8+ T cells isolated from naive WT and Spred2-/- mice were cultured with plate-bound 10 lg/mL anti-CD3 Ab plus 1 lg/mL anti-CD28 Ab for 48 h.
IFNc levels in the culture supernatants were measured by ELISA (4 samples, each group). (F) CD4+ and CD8+ T cells from naive Spred2-/--spleens were stimulated in vitro with
10 lg/mL Con A with 10 lM U0126 or DMSO for 24 h, and IFNc levels in the supernatants were determined (4 mice for each group). (G) CD4+ and CD8+ T cells from Spred2-/-
mice were cultured with 10 lM U0126 or DMSO simultaneously with plate-bound 10 lg/mL anti-CD3 Ab plus 1 lg/mL anti-CD28 Ab for 48 h. IFNc levels in the supernatants
were measured by ELISA (4 samples, each). *p < 0.05., **p < 0.01., ****p < 0.0001.
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Fig. 6. Enhanced CXCL9 and CXCL10 mRNA expression in Spred2-/--livers. (A) Hepatic mRNA levels of CXCL9 and CXCL10 in WT and Spred2-/- mice at indicated time after
10 mg/kg Con A challenge were quantitated by RT-qPCR (4 mice each). (B) Spred2-/- mice were treated with anti-IFNc IgG (1 mg/mouse) or control rabbit IgG 12 h prior to
10 mg/kg Con A challenge. Hepatic mRNA levels of CXCL9 and CXCL10 at 12 h post Con A challenge were quantitated by RT-qPCR (3–5 mice, each). (C) WT and Spred2-/- mice
were intraperitoneally administered with 10 lmol/kg U0126 or DMSO 3 h prior to 10 mg/kg Con A challenge. mRNA levels of CXCL9 and CXCL10 in livers at 12 h post Con A
challenge were analysed by RT-qPCR (4 mice for each group). (D) Hepatocytes isolated from naive WT and Spred2-/- mice were cultured with 40 ng/mL IFNc for 6 h. mRNA
levels of CXCL9 and CXCL10 in livers were quantitated by RT-qPCR (n = 3). *p < 0.05., **p < 0.01., ***p < 0.001., ****p < 0.0001.
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forin and granzyme B mRNA expressions in Spred2-/--livers were
higher than WT controls (Fig. 8B). Of note, number of infiltrating
CD8+ T cells was larger than WT controls (Fig. 5B). Thus, enhanced
CD8+ T cell-mediated cytotoxicity by perforin and granzyme B per
organ-basis may be involved in more severe hepatocyte damage in
mice with Spred2-deficiency.10It is reported that IFNc can directly cause hepatotoxicity [39].
To examine whether Spred2-deficiency in hepatocytes could affect
IFNc-hepatotoxicity, primary hepatocytes from naive mice were
stimulated with IFNc in vitro and levels of LDH, a cell death marker,
were measured. As a result, there was no difference between WT-
and Spred2-/--hepatocytes (Fig. 8C), indicating that Spred2-
deficiency in hepatocytes does not affect the sensitivity to
Fig. 7. CD4+ and CD8+ T cells are responsible for Con A-hepatotoxicity. (A-C) Spred2-/- mice were intraperitoneally administered with anti-CD4+ and anti-CD8+ IgG
(100 mg/mouse) or control rat IgG 12 h prior to 10 mg/kg Con A challenge. (A) Left, ALT levels in the sera at 12 h post Con A challenge were measured (3–4 mice, each). Right,
representative photographs of liver sections are shown (scale bar, 100 mm). %injured area was semi-quantitated using cellSens Standard software. (B) Serum levels of IFNc at
12 h post Con A challenge were evaluated by ELISA (3–4 mice, each). (C) IFNc mRNA levels in livers at 12 h post Con A challenge were quantitated by RT-qPCR (3–4 mice,
each). (D-I) RAG1-/- mice were intravenously administered through tail vein with CD4+ T cells (2.5  106 cells/mouse) (D-F, 4 mice each) or CD8+ T cells (5  106 cells/mouse)
(G-I, 4 mice each) isolated from WT or Spred2-/- mice 1 week before 10 mg/kg Con A challenge. (D,G) ALT levels in the sera at 12 h post Con A challenge were measured. (E,H)
Left, representative photographs of liver sections are shown (scale bar, 100 mm). Right, %injured area was semi-quantitated using cellSens Standard software. (F,I) IFNc levels
in sera were measured. *p < 0.05., **p < 0.01., ***p < 0.001., ****p < 0.0001.
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higher than WT mice (Fig. 2A,B). Therefore, it is possible that
increased overall IFNc results in exacerbated liver damage in11Spred2-/- mice. Altogether, CD4+ T cells, and to a certain degree
CD8+ T cells, appear to contribute to the exacerbated liver damage
in Spred2-/- mice by producing higher IFNc production.
Fig. 8. Hepatocyte damage by CD4+/CD8+ T cells and IFNc. (A) Hepatic CD4+ and CD8+ T cells were isolated fromWT and Spred2-/- mice at 12 h post 10 mg/kg Con A challenge,
and perforin and granzyme BmRNA expressions were quantitated by RT-qPCR (n = 6, each time point). (B) mRNA expressions of perforin and granzyme B in WT and Spred2-/--
livers at 12 h post 10 mg/kg Con A challenge were quantitated by RT-qPCR (n = 4, each time point). (C) Hepatocytes isolated from naive WT and Spred2-/- mice were cultured
with 40 ng/mL IFNc for 48 h. Levels of LDH in the culture supernatants were determined (n = 3 each). *p < 0.05., **p < 0.01., ***p < 0.001., ****p < 0.0001, ns: not significant.
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decreased number of infiltrating CD4+ and CD8+ T cells and IFNc
production
Above results suggested that Con A-hepatoxicity can be
improved by overexpression of Spred2. To address this, we
employed Spred2 transgenic (Spred2Tg) mice. No difference was
found in serum ALT level between naive WT and Spred2Tg mice
(29.0 ± 1.7 vs 30.3 ± 2.8 IU/L, respectively, 3 mice each). As
expected, Con A-induced liver damage was markedly improved
in Spred2Tg mice relative to WT mice with decreased ALT levels
(Fig. 9A) and reduced injured area (Fig. 9B) 12 h post Con A chal-
lenge. Activation of ERK and Stat1 at 12 h post Con A challenge
was decreased in Spred2Tg-livers, as compared to WT-livers
(Fig. 9C). The numbers of infiltrating total leukocytes (Fig. 9D)12and CD4+ and CD8+ T cells (Fig. 9E) were decreased in Spred2Tg-
livers. Levels of serum IFNc and hepatic IFNc mRNA expression
were lower in Spred2Tg mice than WT mice (Fig. 9F,G). CXCL10
mRNA expression was also decreased in Spred2Tg-livers as com-
pared to WT controls, although CXCL9 levels were not statistically
different between the groups (Fig. 9G). To examine whether Spred2
overexpression affects IFNc production by T cells, splenocytes
were isolated from Con A-treated WT and Spred2Tg mice and cul-
tured for 24 h without additional stimulation. As shown in Fig. 9H,
splenocytes from Spred2Tg mice released lower level of IFNc than
WT controls. When splenocytes isolated from naive WT and
Spred2Tg mice were stimulated with Con A in vitro, IFNc produc-
tion was significantly reduced in Spred2Tg-splenocytes as com-
pared to WT controls (Fig. 9I) with decreased ERK activation
(Fig. 9J). Upon stimulation with Con A in vitro, IFNc production
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controls (Fig. 9K). Thus, Spred2 overexpression improves Con A-
hepatotoxicity by reducing IFNc production from CD4+ and CD8+
T cells, further confirming the significant impact of Spred2 on T cell
IFNc production and T cell-mediated liver damage.
Discussion
In the present study, we demonstrated that Spred2 that nega-
tively regulates ERK-MAPK is protective during Con A-induced
liver damage via decreased IFNc production from CD4+ and CD8+
T cells. CD4+ T cells are the main sources of IFNc [40] and are harm-
ful immune cell subsets in Con A-hepatotoxicity [8]. CD8+ T cells
were accumulated in livers after Con A challenge in mice [41]
and in livers from patients with AIH [42]. IFNc production was
detected in CD8+ T cells after Con A-challenge [9]. Here, we showed
by the depletion and transplantation of CD4+ and CD8+ T cells that
Spred2-deficiency in CD4+ and CD8+ T cells are responsible for the
augmented IFNc production, leading to the exacerbated Con A-
hepatotoxicity.
T cell antigen receptor (TCR) ligation leads to the activation of
ERK and subsequent IFNc production [30]. In addition to Con A,
direct activation of TCR on CD4+ and CD8+ T cells with anti-CD3/
CD28 also resulted in increased IFNc production by Spred2-/--T
cells in vitro. Activation of ERK and Stat1 was enhanced in Spred2-/–
splenocytes, and the Stat1 activation was inhibited by a MAPK/ERK
inhibitor U0126. Activation of Stat1 as well as ERK was decreased
in livers of Con A-treated Spred2Tg mice. Further, IFNc production
by splenocytes and CD4+/CD8+ T cells from Spred2Tg mice was
decreased as compared to WT T cells. These results suggest that
endogenous Spred2 can inhibit IFNc production by CD4+ and
CD8+ T cells by modulating the ERK/MAPK pathway that also influ-
ences the Stat1 pathway. We examined the expression of Spred2
mRNA in WT-CD4+ and CD8+ T cells after stimulation with Con A
in vitro. Spred2 mRNA level increased at 6 h but dramatically
decreased by 12 h and remained low at 24 h, which may allow
more efficient IFNc production by T cells (Fig. S2). It will be inter-
esting to examine the mechanism(s) of Spred2 expression in T cells
and the impact of Spred2 in other functions of T cells.
Stat1 and Stat3 were previously shown to regulate each other in
Con A-induced liver injury. Disruption of Stat1 attenuated Con A-
liver injury, but enhanced Stat3 activation and Stat3-controlled
antiapoptotic signals. Downregulation of Stat3 activation was asso-
ciated with enhanced Stat1 activation and Stat1-induced exacerba-
tion of liver injury, suggesting opposing roles of Stat1 and Stat3 in
T cell-mediated hepatitis thorough the induction of suppressor of
cytokine signaling (SOCS) [29]. In our study, both Stat1 and Stat3
were activated in WT-livers after Con A challenge. Since Stat1 acti-
vation was enhanced in Spred2-/--livers by increased IFNcFig. 9. Spred2Tg mice exhibit reduced Con A-induced liver damage. (A) Serum ALT levels
6 mice, Spred2Tg; 4 mice). (B) Left; liver sections from WT and Spred2Tg mice at 12 h po
using the cellSens Standard software (WT; 6 mice, Spred2Tg; 4 mice). (C) Liver extracts a
antibodies (3 mice each). Band densities were digitised and semi-quantitated. (D) The nu
(4 mice, each). (E) Hepatic leukocytes were stained with fluorescence-labelled antibodies
each). (F) Serum IFNc level was measured by ELISA at 12 h post 10 mg/kg Con A challenge
WT and Spred2Tg-livers at 12 h post 10 mg/kg Con A challenge were quantitated by R
Spred2Tg mice at 12 h post 10 mg/kg Con A challenge were cultured for 24 h without add
Splenocytes isolated from naive WT and Spred2Tg mice were cultured with 10 lg/mL C
isolated from naive WT and Spred2Tg mice were cultured with 10 lg/mL Con A for 30 mi
the indicated primary antibodies (3 each). Band densities were digitised and semi-quan
cultured with 10 lg/mL Con A for 24 h, and IFNc levels in the culture supernatants wer
14response, Stat3 activation could be altered in Spred2-/--livers. How-
ever, no difference was found in Stst3 activation in Spred2-/--livers
as compared to WT-controls. In response to IFNc, not only Stat1
but Stat3 can be weakly activated [43], in which Stat1-
independent induction of SOCS3 by IFNc may play a role [44].
Thus, activation of Stat1 and Stat3 in response to IFNc may vary
under different conditions. Further research is needed to address
this possibility.
Our results suggest that Spred2-deficiency in T cells plays a cen-
tral role in the enhanced Con A-hepatotoxicity. However, other cell
types, including macrophages, neutrophils and hepatocytes, can
also be stimulated by IFNc in vivo. Enhanced ERK and Stat1 activa-
tion in the liver could be due to the activation of these cells. We
recently generated myeloid cell-specific Spred2-/- mice, by crossing
Spred2-floxed mice with LysMCre mice [45]. LysMcre mice are use-
ful to delete genes in myeloid cells, including macrophages, neu-
trophils [46] and Kupffer cells [47]. No differences were observed
in serum ALT levels, hepatic number of CD4+ and CD8+ T cells, or
hepatic IFNc/TNFa/CXCL9/CXCL10 mRNA expression levels
between LysMCre+:Spred2fl/fl and Spred2fl/fl mice (Fig. S5). Macro-
phages and Kupffer cells are known as the cellular sources of
CXCL9 and CXC10 in Con A-hepatitis [35]. Although we previously
showed that Spred2-/--Kupffer cells expressed higher levels of
CXCL9 and CXCL10 after stimulation with IFNc [18], CXCL9 and
CXCL10 production appears to be more dependent on hepatocytes
than Kupffer cells in Con A-hepatotoxicity. Considering the results
obtained by myeloid cell-specific Spred2-/- mice and Spred2-/--
hepatocytes, deficiency of Spred2 in myeloid cells or hepatocytes
does not appear involved in the enhanced hepatotoxicity.
Chemokines are important in the development of inflammation
by attracting diverse inflammatory cells into injured tissues. In this
study,CXCL9andCXCL10mRNAexpressions inSpred2-/--liverswere
higher thanWT controls, whichwere significantly inhibited by neu-
tralization of IFNc. A MAPK/ERK inhibitor U0126 decreased CXCL9
and CXCL10 mRNA expression in Spred2-/--livers after Con A chal-
lenge. Thus, enhanced IFNc production in Spred2-/- mice results in
enhanced production of CXCL9 and CXCL10 through ERK/MAPK.
Hepatocytes are known to produce CXCL9 and CXCL10 upon IFNc
stimulation [35,36]. We showed in this study that Spred2-/--
hepatocytes expressed augmented levels of CXCL9 and CXCL10 after
stimulation with IFNc. Thus, it appears that Spred2-deficiency in
CD4+ and CD8+ T cells leads to higher IFNc level in response to Con
A, and this increased level of IFNc stimulates hepatocytes to produce
CXCL9 and CXCL10. CXCL9 and CXCL10 attract CD4+ and CD8+ T cells
[48,49]. ElevatedhepaticCXCL9andCXCL10 inSpred2-/-mice recruit
additional CD4+ and CD8+ T cells in livers, which then lead to addi-
tional IFNc secretion that induces elevated CXCL9 and CXCL10 pro-
duction in livers. Based on this positive feedback loop, Con A-
hepatotoxicity appears to be exacerbated in Spred2-/- mice.in WT and Spred2Tg mice were measured post 12 h 10 mg/kg Con A challenge (WT;
st 10 mg/kg Con A challenge (scale bar, 100 mm). Right; %injured area was estimated
t 12 h post 10 mg/kg Con A challenge were immunoblotted with indicated primary
mbers of infiltrating leukocytes at 12 h post 10 mg/kg Con A challenge were counted
and percentages of leukocyte populations were analyzed by flow cytometry (4 mice,
(WT; 6 mice, Spred2Tg; 4 mice). (G) IFNc, CXCL9 and CXCL10 mRNA expressions in
T-qPCR (WT; 6 mice, Spred2Tg; 4 mice). (H) Splenocytes harvested from WT and
itional stimulation (n = 6). IFNc levels in the culture supernatants were measured. (I)
on A for 24 h and IFNc levels in the supernatants were determined. (J) Splenocytes
n and 2 h. The level of each protein in cells was evaluated by Western blotting using
titated. (K) CD4+ and CD8+ T cells from untreated WT- and Spred2Tg-spleens were
e determined (n = 5, each). *p < 0.05., **p < 0.01., ***p < 0.001.
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Our results demonstrated that Spred2-deficiency results in
increased IFNc production by CD4+ and CD8+ T cells and more sev-
ere liver damage due to up-regulated ERK in response to Con A
injection. Conversely, Spred2 overexpression decreases IFNc pro-
duction by CD4+ and CD8+ T cells and improves Con A-
hepatotoxicity. Furthermore, Spred2 overexpressing-splenocytes,
-CD4+ and -CD8+ T cells produced lower levels of IFNc than WT
controls upon stimulation with ConA in vitro. These results indicate
that Spred2 is a novel regulator of T cell IFNc production and
Spred2-mediated inhibition of the ERK-MAPK pathway may be a
new remedy for T cell-dependent liver damage.Compliance with Ethics Requirements
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